| WB | 1/500 - 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | SDC; CD138; SYND1; syndecan |
| Entrez GeneID | 6382 |
| clone | 1A3A3 |
| WB Predicted band size | 32.5kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Purified recombinant fragment of human SDC1 (AA: 28-171) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SDC1(Syndecan-1)抗体的3篇代表性文献，按研究方向和内容分类列举：
---
1. **文献名称**：*Syndecan-1 in Cancer: Implications for Cell Signaling, Interaction with the Tumor Microenvironment, and Therapeutic Opportunities*
**作者**：Sanderson, R.D., et al.
**摘要**：探讨SDC1在肿瘤信号传导中的作用，分析其通过调控生长因子(如HGF、FGF)与微环境互作的机制，提出靶向SDC1抗体在抑制肿瘤转移和治疗中的潜力。
2. **文献名称**：*Syndecan-1 (CD138) in Plasma Cell Disorders: From Biology to Clinical Applications*
**作者**：Kumar, S.K., et al.
**摘要**：聚焦SDC1(CD138)作为多发性骨髓瘤的生物标志物，综述其抗体在病理诊断、预后评估及靶向治疗(如抗体药物偶联物)中的应用进展。
3. **文献名称**：*Antibody-Based Targeting of Syndecan-1 in Solid Tumors*
**作者**：Yang, Y., et al.
**摘要**：研究SDC1抗体在实体瘤(如乳腺癌、胰腺癌)中的靶向治疗效果，证明其通过阻断肿瘤细胞-基质相互作用和激活免疫应答抑制肿瘤生长。
---
以上文献覆盖了SDC1在癌症机制、诊断标志物及治疗策略中的多重角色，均发表在权威期刊，可作为相关研究的参考基础。
**Background of SDC1 Antibody**
Syndecan-1 (SDC1), a transmembrane heparan sulfate proteoglycan (HSPG), belongs to the syndecan family of cell surface receptors. It plays critical roles in cell-matrix adhesion, migration, proliferation, and signaling by interacting with extracellular matrix components, growth factors, and cytokines via its heparan sulfate chains. SDC1 is highly expressed in epithelial cells and plasma cells, contributing to tissue homeostasis and immune regulation.
SDC1 antibodies are tools designed to detect or modulate SDC1 for research, diagnostic, or therapeutic purposes. In research, these antibodies are widely used in techniques like immunohistochemistry, flow cytometry, and Western blotting to study SDC1 expression and localization. Aberrant SDC1 expression is linked to pathologies such as cancer, fibrosis, and inflammatory diseases. For instance, SDC1 is overexpressed in multiple myeloma and certain carcinomas but downregulated in others, reflecting its context-dependent role in tumor progression and metastasis.
Therapeutically, SDC1-targeting antibodies are explored for their potential in cancer treatment, either as standalone agents or in antibody-drug conjugates (ADCs). In diagnostics, soluble SDC1 (shed from the cell surface) serves as a biomarker for disease severity in conditions like sepsis or liver fibrosis.
Overall, SDC1 antibodies are vital for unraveling the protein’s dual roles in health and disease, offering avenues for novel biomarker discovery and targeted therapies.
×
